Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension

Hypertension Research

Volumn 35, Issue 1, 2012, Pages 93-99

  Ito, Hiroshi ^a   Ishii, Katsuhisa ^b   Kihara, Hajime ^c   Kasayuki, Noriaki ^d   Nakamura, Fumiaki ^e   Shimada, Kenei ^f   Fukuda, Shota ^g   Iwakura, Katsuomi ^h   Yoshikawa, Junichi ⁱ  

^a OKAYAMA UNIVERSITY   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c Kihara Cardiovascular Clinic   (Japan)

^d Ishikiriseiki Hospital   (Japan)

^e Ibaraki Iseikai Hospital   (Japan)

^f Osaka City University   (Japan)

^g Osaka Ekisaikai Hospital   (Japan)

^h Diagnostic Cardiology and Radiology Department   (Japan)

ⁱ Nishinomiya Watanabe Cardiovascular Center   (Japan)

Author keywords

diastolic function; echocardiography; heart failure; hemodynamics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; NATRIURETIC FACTOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DIZZINESS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE RELAXATION; HEART PRELOAD; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FUNCTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; PHOTOSENSITIVITY; RASH; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HEART FAILURE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84855466040     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.169     Document Type: Article

References (25)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562. (Pubitemid 26154241)
2. Aurigemma GP. Diastolic heart failure-a common and lethal condition by any name. N Engl J Med 2006; 355: 308-310. (Pubitemid 44079347)
3. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, on behalf of PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345. (Pubitemid 44453578)
4. Massie VM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, for the I-PRESERVE Investigators. Irbesartan inpatients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
5. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. (Pubitemid 37093918)
6. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Role of diuretics in the prevention of heart failure. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2006; 113: 2201-2210.
7. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL, Stamler J, for the SHEP Cooperative Research Group. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch Intern Med 1998; 158: 741-751. (Pubitemid 28204659)
8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463. (Pubitemid 41821197)
9. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourciè re Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP, for the Valsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007; 369: 2079-2087 (VALIDD). (Pubitemid 46935945)
10. Ito H, Ishii K, Iwakura K, Nakamura F, Nagano T, Takiuchi S, for the Clinical impact of Azelnidipine on Left VentricuLar diastolic function and OutComes in patients with hypertension (CALVLOC) trial investigators. Impact of Azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography. Hypertension Res 2009; 32: 895-900.
11. Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, do Rocha R, Pitt B, for the Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension 2010; 55: 241-248.
12. Carlsson M, Ugander M, Mosen H, Buhre T, Arheden H. Atrioventricular plane displacement is the major contributor to left ventricular pumping in healthy adults, athletes, and patients with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007; 292: H1452-H1459. (Pubitemid 46377133)
13. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456-1462. (Pubitemid 39238023)
14. Smith GD, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GDO, Day INM, Ebrahim S. Association of C-reactive protein with blood pressure and hypertension: Life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25: 1051-1056. (Pubitemid 40627854)
15. Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail 2008; 10: 63-69.
16. Lagrand WK, Visser CA, Hermens WT, Niessen HWM, Verheugt FWA, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102. (Pubitemid 29297946)
17. Blake GJ, Rifai N, Burning JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999. (Pubitemid 37553568)
18. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of Creactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
19. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001; 6: 95-103. (Pubitemid 32328172)
20. Doust JA, Pietrzak E, Dobson A. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625.
21. Ristow B, Ali S, Whooley MA, Schiller NB. Usefulness of left atrial volume index to predict heart failure hospitalization and mortality in ambulatory patients with coronary heart disease and comparison to left ventricular ejection fraction (from the Heart and Soul Study). Am J Cardiol 2008; 102: 70-76.
22. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlö f B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356. (Pubitemid 39491919)
23. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A, Shigamasa C, Yamamoto Y, Ninomiya H, Hisatome I. Uricosuric action of Losartan via the Inhibition of Urate transporter 1 (URAT 1) in hypertensive patient. Am J Hypertension 2008; 21: 1157-1162.
24. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first line therapy in hypertension. Circulation 2008; 117: 2706-2715.
25. Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, Wright Jr JT. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 2008; 52: 30-36.